Business
CEPI and Samsung Biologics collaborate to strengthen outbreak-ready vaccine production and global access
The Coalition for Epidemic Preparedness Innovations (CEPI) and Samsung Biologics (KRX: 207940.KS), a leading contract development and manufacturing organization (CDMO), today announced a partnership to strengthen vaccine manufacturing preparedness for future epidemic and pandemic threats. The collaboration will see Samsung Biologics join CEPI's Vaccine Manufacturing Facility Network (VMFN) with the aim of accelerating the availability of protein-based vaccines and advancing equitable access to t
About this update from Samsung Biologics Co., Ltd.
[{"type":"text","content":"OSLO, Norway and INCHEON, South Korea, Feb. 3, 2026 /PRNewswire/ -- The Coalition for Epidemic Preparedness Innovations (CEPI) and Samsung Biologics (KRX: 207940.KS), a leading contract development and manufacturing organization (CDMO), today announced a partnership to strengthen vaccine manufacturing preparedness for future epidemic and pandemic threats. The collaboration will see Samsung Biologics join CEPI's Vaccine Manufacturing Facility Network (VMFN) with the aim of accelerating the availability of protein-based vaccines and advancing equitable access to those vaccines during future outbreaks in Low- and Middle-Income Countries (LMICs).","length":659,"tagName":"p"},{"type":"image","alt":"CEPI and Samsung Biologics collaborate to strengthen outbreak-ready vaccine production and global access","displaySize":"","headline":null,"caption":"CEPI and Samsung Biologics collaborate to strengthen outbreak-ready vaccine production and global access","className":"","disableSlideshowImg":false,"size":{"original":{"width":400,"height":297,"url":"https://media.zenfs.com/en/prnewswire.com/e2ee0e1763645e217e00d2b987f4808e"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/lx.QSDrMJxCTrhr0Si_UWg--/YXBwaWQ9aGlnaGxhbmRlcjt3PTcwNTtoPTUyMztjZj13ZWJw/https://media.zenfs.com/en/prnewswire.com/e2ee0e1763645e217e00d2b987f4808e","width":400,"height":297}},"href":"https://mma.prnewswire.com/media/2875543/1st_photo.html","hrefExternal":true,"rel":"nofollow"},{"type":"text","content":"Supported by an initial budget of up to US$20 million, CEPI will work with Samsung Biologics to establish a scalable, rapid manufacturing process for recombinant-protein vaccines. This will include leveraging Samsung Biologics' well-established mammalian cell-based infrastructure — a flexible system that plays a key role in manufacturing protein-based products efficiently and at a very large scale — and its mature quality and regulatory systems. The aim is to pre-position a ready-to-activate process that can be deployed quickly when a new viral threat emerges, giving protein-based vaccines a rapid response capability in future.","length":639,"tagName":"p"},{"type":"image","alt":"Product line","displaySize":"","headline":null,"caption":"Product line","className":"","disableSlideshowImg":false,"size":{"original":{"width":400,"height":266,"url":"https://media...